Thomas DiRaimondo, Ph.D.

Thomas DiRaimondo, Ph.D.

Chief Scientific OfficeratJanux Therapeutics· In proxies 2024–2025

Pay in FY2025+27% from the year before · Janux Therapeutics stock -74.2% the same year

Thomas DiRaimondo, Ph.D. was paid $4.3M in FY2025 (Dec), up 27%. Janux Therapeutics stock fell 74.2% that year.

Pay$100 in the stock at the end of FY23 → $129
Pay is from the Summary Compensation Table of each Janux Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Janux TherapeuticsPublic company · 2 yr
    • Chief Scientific Officer2024 – Present · 2 yrStock in role +73%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?